illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. Neuca Group
Company logo

Neuca Group | Sustainability Performance

https://www.neuca.pl/en/
Linkedin

Is a company that operates in the healthcare sector, primarily as a wholesaler of pharmaceuticals.

1990

Poland

5,001 - 10,000 employees

Pharmaceuticals

$1B - 10B in revenue

$25M - 100M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#9561
Overall
#57
in Poland
#228
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and exclusionsB-corp & CDP
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
Selvita

Poland, Hospital & Health Care, Biotechnology

Company logo
Ryvu Therapeutics

Poland, Hospital & Health Care, Biotechnology

Company logo
Industri Jamu Dan Farmasi Sido Muncul

Indonesia, Hospital & Health Care, Pharmaceuticals

Market cap

14.4B $, 2026▲8.6% YoY

Revenue

3.6B $, 2025▲7.6% YoY

R&D intensity

0% 2025

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Neuca SA, Polish major pharma wholesale, has faced sustained Polish UOKiK competition enforcement scrutiny over alleged anticompetitive practices in Polish pharma distribution, plus periodic class actions over alleged inadequate disclosure of Polish pharma wholesale customer concentration affecting Polish institutional shareholders amid Polish pharmaceutical wholesale sector consolidation pressure.
Powered by illuminem

Market cap

14.4B $, 2026▲8.6% YoY

Revenue

3.6B $, FY2025▲7.6% YoY

EBITDA

62.0M $, FY2025▼9.1% YoY

Operating margin

2% Industry: -24▼27.2% YoY

Revenue & EBITDA

$3.6BFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends

Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

-7.9M 2024▲753.9% YoY

Capex

24.5M 2024▼2.2% YoY

Debt/equity ratio

0.8 Industry: 0▼NaN% YoY

R&D intensity

0.0%FY2025

R&D as % of revenue

R&D as % of revenue
Industry benchmark

Powered by illuminem

Return on invested capital

8.0%FY2026
Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals

Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

3.1

▼ 4.1%

2023

3.4

▼ 1.6%

2024

3.6

▲ 0.7%

2025

17.8

2031

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Available

Recycling policy

Available

Workplace health & safety policy

Available

0%
Independent Directors

0 out of 13 incl. management

Powered by illuminem

Overall score

66

Environment

72

Social

99

Governance

28

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

CDP Scores

Climate Score

Not disclosed

A

A-

B

B-

C

C-

D

D-

Powered by illuminem and GIST impact

Reporting

sustainability report symbol

Sustainability Report

 Available
Not committed to key sustainability initiatives

Sustainability employees

Total sustainability employees

7-10

    Available in
    Scale package

    Access
  • Email
  • Email